Last reviewed · How we verify
tNIV Vaccine
At a glance
| Generic name | tNIV Vaccine |
|---|---|
| Also known as | Trivalent Nanoparticle Influenza Hemagglutinin Vaccine |
| Sponsor | Novavax |
| Modality | Biologic |
| Phase | Phase 3 |
Approved indications
Common side effects
Key clinical trials
- A Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine and Influenza Combination Vaccine (PHASE3)
- Lot Consistency Study of COVID-19 and Influenza Combination Vaccine (PHASE2, PHASE3)
- Phase 3 Lot Consistency Study of Trivalent Hemagglutinin Nanoparticle Influenza Vaccine (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- tNIV Vaccine CI brief — competitive landscape report
- tNIV Vaccine updates RSS · CI watch RSS
- Novavax portfolio CI